Bavarian Nordic hit by cancer immunotherapy failure
admin 18th September 2017 Uncategorised 0Bavarian Nordic saw its shares plummet as much as 50 percent in the wake of news that the firm’s cancer immunotherapy ProstVac failed to prolong survival in men with a particular type of prostate cancer.
More: Bavarian Nordic hit by cancer immunotherapy failure
Source: News